Impact of polymeric nanoparticles on oral pharmacokinetics: A dose-dependent case study with estradiol

Journal of Pharmaceutical Sciences

Volumn 98, Issue 10, 2009, Pages 3730-3734

  Mittal, G ^a,b   Kumar, M N V Ravi ^a  

^a NATIONAL INSTITUTE OF PHARMACEUTICAL EDUCATION AND RESEARCH NIPER   (India)

^b UNIVERSITY OF STRATHCLYDE   (United Kingdom)

Author keywords

Bioavailability; Nanoparticles; Oral drug delivery; Pharmacokinetics; Polymers

Indexed keywords

ESTRADIOL; RESOMER;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG DOSE INCREASE; DRUG ELIMINATION; DRUG FORMULARY; DRUG HALF LIFE; DRUG RELEASE; MALE; MAXIMUM PLASMA CONCENTRATION; MEAN RESIDENCE TIME; NONHUMAN; RAT; TIME TO MAXIMUM PLASMA CONCENTRATION;

EID: 70349236977     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.21695     Document Type: Article

References (14)

1. Lobo RA. 1995. Benefits and risks of estrogen replacement therapy. Am J Obstet Gynecol 173:982-989.
2. Yager JD, Liehr JG. 1996. Molecular mechanism of estrogen carcinogenesis. Annu Rev Pharmacol Toxicol 36:203-232.
3. Faulds D, Goa KL, Benfield P. 1993. Cyclosporin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in immunoregulatory disorders. Drugs 45:953-1040.
4. Yoo JW, Lee CH. 2006. Drug delivery systems for hormone therapy. J Control Release 112:1-14. (Pubitemid 43963297)
5. Italia JL, Bhardwaj V, Kumar MNVR. 2006. Disease, destination, dose and delivery aspects of ciclosporin: The state of the art. Drug Discov Today 11:846-854. (Pubitemid 44280030)
6. Jani PU, McCarthy DE, Florence AT. 1992. Nanosphere and microsphere uptake via Peyer's patches: Observation of the rate of uptake in rat after a single oral dose. Int J Pharm 86:239-246.
7. Desai MP, Labhasetwar V, Amidon GL, Levy RJ. 1996. Gastrointestinal uptake of biodegradable microparticles: Effect of particle size. Pharm Res 13:1838-1845. (Pubitemid 27034116)
8. Florence AT. 1997. The oral absorption of microand nanoparticulates: Neither exceptional nor unusual. Pharm Res 14:259-266.
9. Hariharan S, Bhardwaj V, Bala I, Sitterberg J, Bakowasky U, Kumar MNVR. 2006. Design of estradiol loaded PLGA nanoparticulate formulations: A potential oral delivery system for hormone therapy. Pharm Res 23:184-195. (Pubitemid 43214675)
10. Italia JL, Bhatt DK, Bhardwaj V, Tikoo K, Kumar MNVR. 2007. PLGA nanoparticles for oral delivery of cyclosporine: Nephrotoxicity and pharmacokinetic studies in comparison to Sandimmune Neoral1. J Control Release 119:197-206. (Pubitemid 46778760)
11. He W, Horn SW, Hussain MD. 2007. Improved bioavailability of orally administered mifepristone from PLGA nanoparticles. Int J Pharm 334:173-178. (Pubitemid 46400316)
12. Mittal G, Sahana DK, Bhardwaj V, Kumar MNVR. 2007. Estradiol loaded PLGA nanoparticles for oral administration: Effect of polymer molecular weight and copolymer composition on release behavior in vitro and in vivo. J Control Release 119:77-85. (Pubitemid 46561546)
13. Sahana DK, Mittal G, Bhardwaj V, Kumar MNVR. 2008. PLGA nanoparticles for oral delivery of hydrophobic drugs: Influence of organic solvent on nanoparticle formation and release behavior in vitro and in vivo using estradiol as a model drug. J Pharm Sci 97:1530-1542.
14. Dhanikula RS, Dhanikula AB, Panchagnula R. 2008. Thermoreversible liposomal poloxamer gel for the delivery of paclitaxel: Dose proportionality and hematological toxicity studies. Pharmazie 63:439-445. (Pubitemid 351955405)